1. Home
  2. CENX vs ERAS Comparison

CENX vs ERAS Comparison

Compare CENX & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Century Aluminum Company

CENX

Century Aluminum Company

HOLD

Current Price

$46.22

Market Cap

4.6B

Sector

Industrials

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$19.29

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CENX
ERAS
Founded
1995
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Aluminum
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
4.0B
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
CENX
ERAS
Price
$46.22
$19.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
12
Target Price
$65.67
$14.25
AVG Volume (30 Days)
1.9M
5.6M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
36.23
EPS
3.23
N/A
Revenue
$1,893,200,000.00
N/A
Revenue This Year
$20.77
N/A
Revenue Next Year
$14.58
N/A
P/E Ratio
$14.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.21
$1.33
52 Week High
$70.43
$24.28

Technical Indicators

Market Signals
Indicator
CENX
ERAS
Relative Strength Index (RSI) 46.63 59.23
Support Level $43.38 $17.63
Resistance Level $47.35 $21.60
Average True Range (ATR) 1.93 1.29
MACD 0.81 -0.16
Stochastic Oscillator 85.76 41.03

Price Performance

Historical Comparison
CENX
ERAS

About CENX Century Aluminum Company

Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. The company also owns a carbon anode production facility in the Netherlands.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: